灯盏细辛注射液治疗脑梗死合并用药的真实世界研究

该文旨在分析灯盏细辛注射液(灯盏细辛)真实世界中治疗脑梗死的人群特征及合并用药情况。通过选择全国20家三甲医院信息系统(HIS)数据库中使用灯盏细辛且主要诊断为脑梗死的2 484例患者用药信息,采用Apriori算法建立模型,使用Clementine 12.0进行关联分析,分析脑梗死合并疾病、灯盏细辛常用合并用药。结果显示患者男性多于女性(1.63:1);年龄>46的中老年人为多,疗程7~14 d占大多数,脑梗死患者多伴有高血压、糖尿病、冠心病等基础疾病;常见合并用药可分为7类:抗血小板治疗药(阿司匹林、氢氯吡格雷)、降血脂药物(阿托伐他汀、普罗布考)、钙离子通道阻滞剂(桂哌齐特)、脑保护剂类药物(吡拉西坦)、改善脑循环药物(前列地尔)、其他活血化瘀中药注射剂(疏血通注射液、血栓通),合并基础疾病的治疗药物:硝苯地平、美托洛尔、硝酸异山梨酯等;患者临床治愈率和好转率达到97.60%。下一步还需要结合临床实际,开展该组合方案的有效性和安全性分析,为临床合理用药提供有益参考。

Real world study of Dengzhan Xixin injection in treatment of cerebral infarction with medication

To analysis of Dengzhan Xixin injection(DZI) in treatment of cerebral infarction (EBHM) in the real world population characteristics and concomitant medication. By selecting the 20 hospital information system(HIS) used in the database of DZI and primary diagnosis of 2 484 cases of cerebral infarction patients information, use the Apriori algorithm to construct the model, using Clementine 12.0 analysis, cerebral infarction complicating diseases, commonly used drug combination analysis of DZI. The results showed that patients with more males than females(1.63:1); age>46 in older persons, treatment 7-14 days accounted for the majority of patients with hypertension,cerebral infarction, diabetes, coronary heart disease and other diseases; common drug combination can be divided into seven categories: medicine of antiplatelet therapy(aspirin, clopidogrel hydrogen), hypolipidemic drugs(atorvastatin, probucol), calcium channel blockers(cinepazide), cerebral protection drugs (laci staw), to improve cerebral circulation drugs (alprostadil), other traditional Chinese medicine injection (Shuxuetong injection, Xueshuantong), treatment with underlying disease: nifedipine, metoprolol, isosorbide dinitrate etc. The clinical cure rate and improvement rate of 97.60%. The next step needs to be combined with clinical practice, carry out analysis of effectiveness and safety of the combination scheme, and provide reference for clinical rational drug use.